ResMed
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.3 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 80.73% +2.34pp
- Institutions
- 1,158 +8
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Michael Farrell | Chairperson & CEO | 0.34% |
| Peter Farrell | Founder, Chair Emeritus & Non-Executive Director | 0.04% |
| Brett Sandercock | Advisor | 0.04% |
| Ronald Taylor | Lead Independent Non-Executive Director | 0.02% |
| Justin Leong | Chief Product Officer | 0.02% |
| Carol Burt | Independent Non-Executive Director | 0.01% |
| Richard Sulpizio | Former Independent Non-Executive Director | 0.01% |
| Michael Rider | Chief Legal Officer | 0.01% |
| Harjit Gill | Independent Non-Executive Director | 0.01% |
| Karen Drexler | Independent Non-Executive Director | 0.01% |
| Kaushik Ghoshal | Former Chief Commercial Officer - SaaS | 0.01% |
| Desney Tan | Independent Non-Executive Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Peter Farrell | Founder, Chair Emeritus & Non-Executive Director | Sale to Issuer | -169 | $234.11 |
| 2026-11-10 | Jan De Witte | Independent Non-Executive Director | Sale to Issuer | -59 | $234.11 |
| 2026-11-10 | Harjit Gill | Independent Non-Executive Director | Sale to Issuer | -35 | $234.11 |
| 2026-11-10 | Michael Farrell | Chairperson & CEO | Sale to Issuer | -8,111 | $234.11 |
| 2026-11-10 | Michael Rider | Chief Legal Officer | Sale to Issuer | -1,943 | $234.11 |
| 2026-11-10 | Aaron Bloomer | Chief Financial Officer | Sale to Issuer | -1,095 | $234.11 |
| 2026-11-08 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,993 | $146.34–235.35 |
| 2026-10-22 | Michael Rider | Chief Legal Officer | Automatic Disposition | -400 | $255.00 |
| 2026-10-06 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,991 | $146.34–226.33 |
| 2026-09-07 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,991 | $146.34–222.44 |
| 2026-09-01 | Peter Farrell | Founder, Chair Emeritus & Non-Executive Director | Automatic Disposition | -970 | $234.73 |
| 2026-08-13 | Justin Leong | Chief Product Officer | Other Acquisition | +6,461 | -- |
| 2026-08-13 | Michael Farrell | Chairperson & CEO | Other Acquisition | +13,547 | -- |
| 2026-08-13 | Michael Rider | Chief Legal Officer | Other Acquisition | +3,230 | -- |
| 2026-08-13 | Aaron Bloomer | Chief Financial Officer | Other Acquisition | +9,072 | -- |
| 2026-08-06 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,991 | $146.34–205.69 |
| 2026-08-04 | Peter Farrell | Founder, Chair Emeritus & Non-Executive Director | Automatic Disposition | -8,000 | $225.00 |
| 2026-07-06 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,991 | $146.34–218.55 |
| 2026-06-07 | Michael Farrell | Chairperson & CEO | Derivative Exercise and Sale | -4,991 | $146.34–193.96 |
| 2026-05-31 | Michael Rider | Chief Legal Officer | Sale to Issuer | -268 | $190.57 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
ResMed discussion 0 comments